It is a privilege to invite you to our 7th Kaunas / Lithuania International Hematology / Oncology Colloquium. Despite having a short history, the meeting has an astonishing record of highlights. Key opinion leaders have reported their latest insights in malignant hematology, stem cell plasticity, gene editing and cellular therapy. This year we tried to pick up again the newest and most relevant achievements in experimental and clinical hematology. We are extremely happy that leading scientists agree to share their insights and visions and are at disposition to exchange experience and answer open questions. Developments in drug discoveries and early clinical studies have led to new recommendations in AML, CML, NPM, MM and other diseases. Some of them are submitted or near to be submitted for publication and will be presented for the first time at the meeting. Furthermore, an important and often underdiagnosed disease named mastocytosis will be presented.  We wanted also to include recent developments in newly diagnosed and resistant/refractory stage M. Hodgkin, a disease never reported at the meeting. Latest news on stem cell transplantation, gene therapy and mRNA technology will be the topic for the third part of the meeting. Finally, we are extremely happy that so many abstracts were submitted. We have selected the best one for a short presentation.

We hope that the colloquium will be useful to you as a physician across different disciplines, as a scientist, as a nurse and as a student. Even if the meeting is hybrid, you will have enough time to discuss on the edge topics with the presenters. Many thanks to the Hospital of Lithuanian University of Health Sciences Kauno Klinikos and the Lithuanian University of Health Sciences for hosting such an outstanding forum.

Thank you for your participation.

Assoc. Prof. Rolandas Gerbutavičius
Prof. Elona Juozaitytė
Prof. Dietger Niederwieser
Dr. Domas Vaitiekus


7th Kaunas / Lithuania International Hematology / Oncology Colloquium
will be held on 26 May 2022 in a hybrid format, attendees are welcome to attend physical venue or join virtually from where is convenient.

- Address for ON-SITE participation: Centre for the Latest Pharmaceutical and Health Technology, Sukileliu Av. 13, Kaunas, Lithuania
- Link for ONLINE participation will be send by email after completed registration latest 23 May 2022

Important dates:
- Poster Abstract submission deadline – 13 May 2022
- Poster submission deadline – 23 May 2022


The Colloquium is intended for hematologists, pediatric hematologists, transfusiologists, clinical toxicologists, allergologists and clinical immunologists, medical oncologists, radiation oncologists, doctors of laboratory medicine, geneticists, biologists, pathologists and doctors of other specialities, scientists and nurses involved in hematopoietic stem cell transplantation.

Colloquium admission is FREE OF CHARGE.
Official Colloquium language – English. Simultaneous translation service will not be provided.

- Possibility to participate On-Site or Online
- Live presentations, Q&A
- Online Posters' Abstract Book
- E-Posters library during the Colloquium and for one year following the Colloquium
- Live Sponsors' Exhibition
- Access to Colloquium record for one month following the Colloquium
- Certificate of Attendance (9 academic hours)



Prof. Dietger Niederwieser (Leipzig, Germany)

Prof. Arturas Inčiūra (Kaunas, Lithuania)
Prof. Rasa Jančiauskienė (Kaunas, Lithuania)
Dr. Laimonas Jaruševičius (Kaunas, Lithuania)
Prof. Elona Juozaitytė (Kaunas, Lithuania)
Assoc. Prof. Rolandas Gerbutavičius (Kaunas, Lithuania)
Assoc. Prof. Sigita Liutkauskienė (Kaunas, Lithuania)
Dr. Domas Vaitiekus (Kaunas, Lithuania)


Assoc. Prof. Rolandas Gerbutavičius (Kaunas, Lithuania)
Prof. Elona Juozaitytė (Kaunas, Lithuania)
Prof. Dietger Niederwieser (Leipzig, Germany)
Dr. Domas Vaitiekus (Kaunas, Lithuania)




You are kindly invited to submit Abstract for Poster Presentation at the 7th Kaunas / Lithuania International Hematology / Oncology Colloquium.

All abstracts should contain the title, full names and workplace of the author(s), city, country and email address. Text of the abstract, excluding the title and all information about the author(s), should not exceed 5000 letters. Submissions must be in English.

Abstract structure:
- Background and objectives
- Material (patients) and research method used
- Findings / results in sufficient details to support conclusions
- Conclusions and recommendations

Please use the form below to submit your Abstract:

All abstracts will be reviewed and selected for Poster presentations session. Authors of accepted abstracts will get confirmation and detailed instructions for Poster presentation by email. The text to abstracts will not be edited, so please pay special attention to correct spelling.

Abstracts should be submitted by e-mail to the address KKOHTD@eventas.lt before 13 May 2022 in .docx format ("Word"). 
The answer about acceptance will be given until 18 May 2022

Authors of selected Poster abstracts will be:
- Invited to prepare E-Poster, which will be available at all times for the delegates during the Colloquium and for one year following the Colloquium 
- Nominated to receive the best poster award


The content of the abstracts presented is the responsibility of their authors and co-authors. 
The abstracts are arranged in sequence alphabetically according to the surname of first author of abstract. Each abstract is reviewed.

Online Poster Abstract Book's Editor
Prof. Elona Juozaityte (Kaunas, Lithuania)

Abstracts’ Reviewers
Abstracts’ Reviewers
Assoc. Prof. Rolandas Gerbutavičius (Kaunas, Lithuania) 
Prof. Arturas Inčiūra (Kaunas, Lithuania)
Prof. Dietger Niederwieser (Leipzig, Germany)
Dr. Domas Vaitiekus (Kaunas, Lithuania)

1. Rita Ambrazienė et al. 
Neoadjuvant intensified chemotherapy vs Standard Therapy in Locally Advanced Rectal Cancer

2. Agnė Bartnykaitė et al. 
PJ-34 Confers Radiosensitizing Effect on MDA-MB-231 Cells

3. Justina Bekampytė et al. 
Association of TIRAP rs8177376 and rs8177374 Polymorphisms with Cervical Cancer Phenotype and Prognosis

4. O.V. Gerasimovich et al. 
Predictors of the Development of Infectious Complications During post Cytostatic Cytopenia in Patients with Acute Leukemia

5. Alan Gutman et al. 
Impact of Hematological Malignancy and Type of Therapy on COVID-19 Severity and Mortality

6. Alena Hlaz et al. 
Results of Allogeneic Hematopoietic Stem Cell Transplantation, Taking Into Account the Characteristics of Unrelated Donors

7. Eglė Juknevičiūtė et al. 
Idiopathic Thrombocytopenic Purpura: Epidemiology in Kaunas County and Treatment Standard

8. Danguolė Laukaitienė et al. 
The Radiosensitizer Potential of Sulforaphane on Breast Cancer Cells

9. Moroz Halyna et al. 
The Interface Between Fatty Acid Composition of Platelet Membrane and Platelet-Leukocyte Aggregates Formation During Stress

10. Nastassia Mukhametshyna et al. 
Harnessing Genetically Engineered Feeder Cell Line for Ex Vivo Expansion of Human Natural Killer Cells with Increased Production of Ifn-Y

11. Pokhylko Valeriy et al. 
The Constraints During Treatment in Pediatric Oncology: Tough Dialogue - a Simple Decision

12. Aistė Savukaitytė et al. 
DDIT4 mRNA Level Determines Aspirin Effect on NDRG1 Expression in MDA-MB-468 Human Breast Cancer Cell Line

13. Tatsiana Shman et al. 
Natural Killer Cell Therapy in Children with Refractory Acute Myeloid Leukemia

14. Igor Skrypnyk et al. 
VRd Regimen for Treatment of Vertebral Plasmacytoma with Spinal Cord Compression

15. Roberta Vadeikienė et al. 
CALR 52 bp Mutation Impairs Oxidative Stress Response and Increases Oxidative Stress-Induced Apoptosis Level in UT-7 Cell Line

16. Audronė Vaitiekienė et al. 
Baseline Evaluation of Cardiac Function and Volumes in Patients Undergoing Hematopoetic Stem Cell Transplantation and Relation to Prior Use of Doxorubicin